C3 glomerulopathies (C3G) are caused by dysregulation of the alternative complement pathway. In >50% of cases, these diseases are associated with expression of autoantibodies known as C3 nephritic ...
Apellis Pharmaceuticals Inc. has identified C3 convertase inhibitors reported to be useful for the treatment of cancer, obesity, infections, neurological disorders, autoimmune and inflammatory ...